Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Product › Details

TandAb bispecific antibody

Products Next higher product group antibody cancer drug
Period Status 2012-03-05 development existent
Organisation Organisation Affimed Therapeutics AG
  Group Affimed (Group)

Affimed Therapeutics AG. (12/5/11). "Press Release: Affimed Therapeutics AG Appoints Dr Eugene Zhukosvky as Chief Scientific Officer". Heidelberg.

Affimed Therapeutics AG, the therapeutic TandAb® antibody company, today announced the appointment of Dr Eugene Zhukovsky as Chief Scientific Officer, effective January 1st 2012.

Dr Zhukovsky joins Affimed from Boehringer Ingelheim Pharmaceuticals as successor to founder and current Chief Scientific Officer Prof Melvyn Little. Prof Little will retire from his position as CSO of the Company and will continue to work as a consultant to Affimed.

Dr Adi Hoess, CEO of Affimed, commented: "We are delighted to welcome an outstanding successor in Dr Eugene Zhukovsky, who will serve as a key member of the Executive Management Board. Eugene has an exceptional track record and brings biotech and pharma drug discovery and development experience, which is important for Affimed as it continues to grow as a leading biopharmaceutical company in the development of bispecific antibodies."

Dr Zhukovsky has 20 years professional experience in the field of biotherapeutics research and development. Previously, he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. Prior to that, Dr Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several therapeutic candidates targeting malignant and normal B cells. One of these therapeutic antibodies is currently undergoing clinical trials. Dr Zhukovsky began his professional career employing phage display technology at Neurex Corporation (now Elan Therapeutics). He then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development at Xencor, Inc.

Dr Thomas Hecht, Chairman of Affimed, added: "On behalf of both, the Supervisory Board and the Executive Management Board, I would like to express my heartfelt thanks to Melvyn for founding Affimed and for his valuable contributions that have been central to building the Company into the success it is today."

Prof Little founded Affimed in 2000 and pioneered the development of Affimed's TandAb® technology as one of the leading bispecific antibody platforms. In 2010, the first TandAb antibody AFM13 entered clinical trials and the bispecific, tetravalent human antibody has shown very promising safety, tolerability and activity in the treatment of Hodgkin Lymphoma. Prof Little became interested in the potential of antibodies for cancer therapy while working at the German Cancer Research Center in Heidelberg and was appointed head of the newly founded research group "Recombinant Antibodies" in 1990. A major task for this unit was to develop methods for generating and screening human antibody libraries using phage display technology. Subsequently, novel approaches were devised for exploiting the potential of the body´s own defence system to kill cancer cells using recombinant bispecific antibodies.

"The TandAb® technology of Affimed Therapeutics is a valuable platform validated by the production of high quality products at a time when substantial efforts in the pharmaceutical industry are directed towards the discovery and development of bifunctional antibodies", said Dr Zhukovsky. "I am delighted to join the company and lead the discovery and preclinical development of drug candidates as well as the continued development of the TandAb® platform for the identification of medications that will benefit patients."

Dr Zhukovsky received his PhD in biochemistry from Brandeis University for studies of GPCR structure-function relationships employing the visual pigment rhodopsin. Prior to this, he completed an MS degree in bioorganic chemistry at St. Petersburg's State University. From 1991 until 1995 Dr Zhukovsky was a Post Doc at Genentech, Inc. where he was engaged in studies evaluating the contribution of secondary structural elements to global protein stability.

About Affimed:

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of anticancer drug candidates based on its proprietary TandAb® technology platform. Affimed's lead product candidate AFM13 for the treatment of Hodgkin's disease is in Phase I clinical development. Both AFM11 and AFM15 to treat Non-Hodgkin's lymphoma and autoimmune diseases, respectively, are in preclinical development. Further novel product candidates are being developed for the treatment of solid tumors, autoimmune diseases and asthma. Affimed's proprietary and highly productive TandAb® technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 30 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg.

Record changed: 2017-04-01


Picture [iito] Männer Ballett 650x80px

More documents for TandAb bispecific antibody

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top